Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • ZENTEL VERSUS FENTEL:...

    ZENTEL VERSUS FENTEL: HC restrains manufacture, sale of medicine for violation of trademark

    Farhat NasimWritten by Farhat Nasim Published On 2019-10-06T11:10:31+05:30  |  Updated On 2021-08-16T16:59:14+05:30

    New Delhi: In a relief to the pharmaceutical giant in a trademark matter, the Delhi High Court has recently restrained the manufacture or sale of Glaxo Smith Kline's (GSK) de-worming drug Albendazole (trade name ZENTEL) tablets and syrups sold under deceptive trade name FENTEL by a manufacturer.


    Albendazole sold under the trade name Zentel is well known as de-worming drug exclusively for human use which is to be sold only on written prescription by a registered medical practitioner (Schedule H Drug).


    Recently, Justice Sanjeev Narula ordered a permanent injunction from manufacturing, selling or offering for sale pharmaceutical preparations under the trade name FENTEL or any other mark which may be deceptively similar to GSK trademark ZENTEL.


    The direction came following a petition filed by GSK when its attention was drawn towards the manufacture and marketing of Albendazole preparation under the mark FENTEL by Faith Pharmaceuticals Ltd and another Samson Laboratories (P) Ltd.


    The firm engaged in making FENTEL contended that GSK was fully aware of the launch and marketing of FENTEL, as the advertisements of both the Companies were appearing side by side in same journals and magazines. In spite of the knowledge of the products manufactured and marketed under the trademark FENTEL, since the year 1998, GSK chose to wait and file the present suit on 9th July 2003. Thus on the ground of delay, laches and estoppel, GSK should not be entitled to relief of injunction and the present suit is liable to be dismissed.


    Also Read: Stop use of trade mark deceptively similar to Glaxo antibiotic Augmentin: Delhi High Court to AFDIL

    After hearing both the parties, the court while referring to previous cases of similar nature dealt by the Supreme court noted that on comparison of the two competing marks ZENTEL and FENTEL, one can easily perceive that there are overwhelming visual, structural and phonetic similarities between the two marks. Both the marks are being used in relation to drugs used for the treatment of the same condition i.e. for de-worming. Both drugs are Schedule H drugs.


    Such drugs are sold by the chemist only on the prescription of a doctor and are not available across the counter. Nevertheless, one cannot lose sight of the ground realities that exist in India where the drugs meant to be sold only on the prescription of a medical practitioner are available across the counter.


    The court ruled in favour of GSK and held;




    "a decree of permanent injunction passed in favour of GSK and against the Defendant whereby Defendants, their Directors, Officers, servants, agents and representatives are restrained from manufacturing, selling or offering for sale pharmaceutical preparations under the trade name FENTEL or any other mark which may be deceptively similar to GSK's trademark ZENTEL and from doing any other such thing so as to cause confusion or deception amounting to passing off of the goods and business of the Defendants as and for those of GSK."



    The court further added;




    "An order to delivery up is passed in favour of GSK directing the Defendants to handover the goods seized by the Local Commissioner which are lying in superdari with the Defendants."



    Also Read: Shocking: 27 medicines including GSK Zentel sold by 18 major drug companies fail quality control
    Albendazole de worming drug Delhi high court fenetel GSK Justice Sanjeev Narula pharma pharma news pharma news india zentel 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X